“Assay”的搜索结果，显示 151-160 项，共有 6062 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   CfDNA Assay Prospective Observational Validation For Early Cancer Detection And Minimal Residual Disease (CAMPERR). Rochester, Minn. The purpose of this ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

5. Mayo Clinic Obstetrics and Gynecology Physician Update - November 2024

   Page 1.

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... assay (IHC) and identified as appropriate for study participation if IHC staining is PS2+ in \>75% of cells (40% of all serous patients). Eligible patients ...

8. 妙佑医疗国际移植中心- 临床试验

   The purpose of the study is to optimize and validate the performance of the Senseera liquid biopsy cfChIP-seq assay for the detection of Acute Cellular ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early- ...

10. 血液科- 临床试验- 妙佑医疗国际

    ... assays using patient peripheral blood immune cells or serum. A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple ...